Status:

COMPLETED

Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer

Lead Sponsor:

Hospices Civils de Lyon

Conditions:

Liver Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

RATIONALE: Iodine I 131 ethiodized oil may help prevent or delay the recurrence of cancer. It is not yet known whether iodine I 131 ethiodized oil is more effective than non-radiolabeled ethiodized oi...

Detailed Description

OBJECTIVES: Primary * Determine whether treatment with adjuvant intra-arterial iodine I 131 ethiodized oil reduces the percentage of tumor recurrence in patients with curatively treated hepatocellul...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of hepatocellular carcinoma (HCC)
  • Alpha-fetoprotein \< 20 ng/mL
  • Must have undergone curative treatment for HCC within the past 8-20 weeks, including 1 of the following:
  • Curative resection
  • Alcohol ablation, radiofrequency ablation, or cryotherapy (for 1 or 2 nodules \< 5 cm in diameter)
  • No ascites
  • No other intrahepatic involvement or nodule progression as assessed by ultrasound
  • No extrahepatic metastases
  • PATIENT CHARACTERISTICS:
  • WHO performance status 0-2
  • ANC ≥ 1,500/mm³
  • Platelet count ≥ 50,000/mm³
  • Bilirubin ≤ 51 μmol/L
  • Creatinine ≤ 120 μmol/L
  • Not pregnant or nursing
  • Negative pregnancy test
  • Child-Pugh score \< 8 (class B)
  • No decompensated cirrhosis
  • No encephalopathy
  • No uncontrolled bleeding
  • No portal thrombosis, right- or left-branch thrombosis, extrahepatic thrombosis, or portal reflux by doppler or CT scan
  • No unstable medical or surgical disease
  • No contraindication to vascular arteriography
  • No history of complications after injection of iodine contrast agents
  • Not incarcerated
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • Recovered from all prior therapy
  • No prior hormonal treatment, including tamoxifen and somatostatin analogs
  • No prior systemic chemotherapy

Exclusion

    Key Trial Info

    Start Date :

    June 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    120 Patients enrolled

    Trial Details

    Trial ID

    NCT00870558

    Start Date

    June 1 2005

    Last Update

    August 16 2011

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Hopital Edouard Herriot - Lyon

    Lyon, France, 69437